Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non- Hodgkin's lymphoma

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 385-387

  Clark, F L ^a   Drummond, M W ^a   Chambers, S ^a   Chapman, B A ^a   Patton, W N ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Chemotherapy; Famciclovir; Hepatitis B virus; Lamivudine; Non Hodgkin's lymphoma

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAMCICLOVIR; LAMIVUDINE; METHOTREXATE; PREDNISONE; VINCRISTINE; VIRUS DNA; VITAMIN K GROUP;

ADULT; ARTICLE; CASE REPORT; DETERIORATION; DOSE RESPONSE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER FAILURE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; VIRUS REACTIVATION;

ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARRIER STATE; FATAL OUTCOME; HEPATITIS B; HUMANS; LAMIVUDINE; LYMPHOMA, B-CELL; LYMPHOMA, HIGH-GRADE; MALE; RECURRENCE;

EID: 0031777382     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008206519571     Document Type: Article

References (10)

1. Kumagai K, Takagi T, Nakamura S et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan. Ann Oncol 1997; 8 (Suppl 1): S107-9.
2. Atra A, Gerrard M, Hobson R et al. Improved cure rate in children with B-ALL and stage IV B-NHL - results of the UKCCSG9003 protocol (submitted).
3. Wands J., Subacute and chronic active hepatitis after withdrawal of chemotherapy Lancet 1975; 2: 979.
4. Lau JYN. Lai CL, Lin HJ et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 911-7.
5. Lok ASF, Liang RHS, Chiu EKW et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100: 182-8.
6. Nakamura Y, Motokura T, Fujita A et al. Severe hepatitis related to chemotherapy in hepatitis B carriers with hematologic malignancies. Cancer 1996; 78: 2210-5.
7. Lai CL, Ching CK, Tung AK et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo controlled trial. Hepatology 1997; 25 (1): 241-4.
8. Honkoop P, de Man RA, Zondervan PE et al. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 1997; 17 (2): 103-6.
9. Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216-23.
10. Perry CM, Faulds D. Lamivudine A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53: 657-80.